Ganglion Cell Complex Thickness and Macular Vessel Density Loss in Primary Open-Angle Glaucoma.
Aged
Cross-Sectional Studies
Female
Fluorescein Angiography
/ methods
Follow-Up Studies
Fundus Oculi
Glaucoma, Open-Angle
/ diagnosis
Gonioscopy
Humans
Intraocular Pressure
/ physiology
Macula Lutea
/ pathology
Male
Middle Aged
Nerve Fibers
/ pathology
Optic Disk
/ pathology
Prospective Studies
Retinal Ganglion Cells
/ pathology
Retinal Vessels
/ pathology
Tomography, Optical Coherence
Visual Fields
Journal
Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
31
07
2019
revised:
12
12
2019
accepted:
27
12
2019
pubmed:
23
2
2020
medline:
15
12
2020
entrez:
23
2
2020
Statut:
ppublish
Résumé
To characterize the change rate of ganglion cell complex (GCC) thickness and macular vessel density in healthy, preperimetric glaucoma and primary open-angle glaucoma (POAG) eyes. Prospective, longitudinal study. One hundred thirty-nine eyes (23 healthy eyes, 36 preperimetric glaucoma eyes, and 80 POAG eyes) of 94 patients who had at least 3 visits were included from the Diagnostic Innovations in Glaucoma Study. The mean follow-up was 2.0 years for healthy eyes, 2.6 years for preperimetric glaucoma eyes, and 2.6 years for POAG eyes. OCT angiography (OCTA)-based vessel density and OCT-based structural thickness of the same 3×3-mm The rates of GCC thinning and macular vessel density loss. Significant rates of GCC thinning and macular vessel density decrease were detectable in all diagnostic groups (all P < 0.05). In healthy eyes and preperimetric glaucoma eyes, the normalized rates of GCC thinning and macular vessel density decrease were comparable (all P > 0.1). In contrast, the normalized rate (mean, 95% confidence interval) of macular vessel density decrease in the POAG eyes (-7.12 [-8.36, -5.88]%/year) was significantly faster than GCC thinning (-2.13 [-3.35, -0.90]%/year; P < 0.001). In the POAG group, more than two thirds of the eyes showed faster macular vessel density decrease than GCC thinning; faster macular vessel density decrease rate was associated significantly with worse glaucoma severity (P = 0.037). The association between GCC thinning rate and glaucoma severity was not significant (P = 0.586). Intraocular pressure during follow-up significantly affected the rate of GCC thinning in all groups (all P < 0.05) but showed no association with the rate of macular vessel density decrease. Both GCC thinning and macular vessel density decrease were detectable over time in all diagnostic groups. In POAG eyes, macular vessel density decrease was faster than GCC thinning and was associated with severity of disease. Macular vessel density is useful for evaluating glaucoma progression, particularly in more advanced disease.
Identifiants
pubmed: 32085875
pii: S0161-6420(20)30014-2
doi: 10.1016/j.ophtha.2019.12.030
pmc: PMC7354893
mid: NIHMS1563524
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1043-1052Subventions
Organisme : NEI NIH HHS
ID : R01 EY011008
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029058
Pays : United States
Organisme : NEI NIH HHS
ID : P30 EY022589
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY027510
Pays : United States
Organisme : NEI NIH HHS
ID : U10 EY014267
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY026574
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Références
Ophthalmology. 2017 Nov;124(11):1589-1599
pubmed: 28676279
Prog Retin Eye Res. 2017 Mar;57:46-75
pubmed: 28012881
Am J Ophthalmol. 2019 Mar;199:120-132
pubmed: 30496723
Am J Ophthalmol. 2014 Jul;158(1):105-112.e1
pubmed: 24709811
Ophthalmology. 2016 Nov;123(11):2309-2317
pubmed: 27592175
Ophthalmology. 2014 Jul;121(7):1322-32
pubmed: 24629312
Am J Ophthalmol. 2017 Oct;182:107-117
pubmed: 28734815
Vestn Oftalmol. 2017;133(2):29-38
pubmed: 28524137
Medicine (Baltimore). 2016 Aug;95(33):e4341
pubmed: 27537559
Am J Ophthalmol. 2016 Nov;171:75-83
pubmed: 27590118
Ophthalmology. 2018 Apr;125(4):578-587
pubmed: 29174012
Surv Ophthalmol. 2009 Jan-Feb;54(1):33-46
pubmed: 19171209
Prog Retin Eye Res. 2013 Jan;32:1-21
pubmed: 22995953
Invest Ophthalmol Vis Sci. 2016 Jul 1;57(9):OCT451-9
pubmed: 27409505
Ophthalmology. 2019 Jul;126(7):980-988
pubmed: 30858023
J Glaucoma. 2017 Oct;26(10):851-859
pubmed: 28858159
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5713-5722
pubmed: 29114838
Br J Ophthalmol. 2018 Mar;102(3):352-357
pubmed: 28739645
Graefes Arch Clin Exp Ophthalmol. 2018 Mar;256(3):589-597
pubmed: 29332249
Br J Ophthalmol. 2017 Dec;101(12):1666-1672
pubmed: 28432111
Ophthalmic Res. 2018;60(3):139-151
pubmed: 29794471
Ophthalmology. 2017 May;124(5):709-719
pubmed: 28196732
Arch Ophthalmol. 2009 Sep;127(9):1136-45
pubmed: 19752422
PLoS One. 2017 Feb 2;12(2):e0170476
pubmed: 28152070
PLoS One. 2017 Mar 13;12(3):e0173930
pubmed: 28288185
Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5862-5867
pubmed: 30550617
J Glaucoma. 2018 Aug;27(8):e137-e139
pubmed: 29762268
Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3637-3645
pubmed: 28728171
Am J Ophthalmol. 2017 Jun;178:38-50
pubmed: 28315655
Sci Rep. 2018 Dec 14;8(1):17866
pubmed: 30552361
PLoS One. 2017 Sep 21;12(9):e0184948
pubmed: 28934255
J Glaucoma. 2018 Mar;27(3):302-305
pubmed: 29303879
J Glaucoma. 2018 Jun;27(6):481-489
pubmed: 29664832
Prog Retin Eye Res. 2002 Jul;21(4):359-93
pubmed: 12150988
Ophthalmology. 2016 Dec;123(12):2498-2508
pubmed: 27726964